Breaking News
September 23, 2018 - Patient Health Information Often Shared Electronically
September 23, 2018 - Can machine learning bring more humanity to health care?
September 23, 2018 - Body organs undergo structural changes in response to diet
September 23, 2018 - Genetic polymorphisms linked with muscle injury and stiffness
September 23, 2018 - As states try to rein in drug spending, feds slap down one bold Medicaid move
September 22, 2018 - Why Eczema Is Tougher to Treat for Black Patients
September 22, 2018 - Team reveals that human genome could contain up to 20 percent fewer genes
September 22, 2018 - USC research uncovers previously unknown genetic risk factor for Alzheimer’s disease
September 22, 2018 - Novel method achieves accurate and precise temperature estimation in fat-containing tissues
September 22, 2018 - BSI accredits Oxehealth’s vital signs measurement software as Class IIa medical device
September 22, 2018 - Evolution of psychiatric disorders and human personality traits
September 22, 2018 - Obesity in early puberty doubles asthma risk for boy’s future offspring
September 22, 2018 - World’s most advanced real-time patient monitoring platform receives key US patent
September 22, 2018 - Study explores connection between sexuality and cognitive status in older adults
September 22, 2018 - LSTM partners with TB Alliance to develop novel TB drug regimens
September 22, 2018 - Annual wellness visits improve delivery of preventive services in elderly population
September 22, 2018 - CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma
September 22, 2018 - Hispanic communities with high proportions of Hispanics face more cardiovascular-related death
September 22, 2018 - Vici syndrome – Genetics Home Reference
September 22, 2018 - Single-dose drug can shorten flu symptoms by about a day, studies suggest
September 22, 2018 - AMSBIO launches circulating tumor DNA Reference Standards
September 22, 2018 - Sandalwood mimicking odorant could stimulate hair growth in humans
September 22, 2018 - Overlooked immune cells could play a key role in cancer immunotherapy, claims new study
September 22, 2018 - Study reveals prevalence of diagnosed type 1 and type 2 diabetes among American adults
September 22, 2018 - Researchers develop fast detection strategy to know type of virus acquired by patients
September 22, 2018 - Global Prevalence of Insufficient Activity 27.5 Percent
September 22, 2018 - Strategies to protect bone health in hematologic stem cell transplant recipients
September 22, 2018 - Brigham Genomic Medicine program unravels 30 medical mysteries
September 22, 2018 - New system harnesses power of bubbles to destroy dangerous biofilms
September 22, 2018 - Inflammation plays crucial role in preventing heart attacks and strokes, study reveals
September 22, 2018 - Calorie dense, nutrient deficient meals common across the world
September 22, 2018 - Researchers develop technology to study behavior of implants without animal testing
September 22, 2018 - First gut bacteria in newborns may have lasting effect on ability to ward off chronic diseases
September 22, 2018 - Detection of BFD virus in parrots in 8 new countries raises concerns for threatened species
September 22, 2018 - Insulin treatment shows great potential against chronic bowel inflammation
September 22, 2018 - ‘Liking Gap’ Might Stand in Way of New Friendships
September 22, 2018 - Simple factors that can avoid harmful side effects in type 2 diabetes
September 22, 2018 - ALSAM Foundation invests additional $2 million for drug discovery and development projects
September 22, 2018 - Study findings may advance discussion of how to effectively curb human-wildlife conflict
September 22, 2018 - Dopamine neurons may involve in conditions ranging from Parkinson’s disease to schizophrenia
September 22, 2018 - Protein C and Protein S Tests: MedlinePlus Lab Test Information
September 22, 2018 - Obesity and diabetes—two reasons why we should be worried about the plastics that surround us
September 22, 2018 - Concern over fussy eating prompts parents to use non-responsive feeding practices
September 22, 2018 - Novel mathematical approach uncovers existence of unsuspected biological cycles
September 22, 2018 - Cancer Research UK invests £14 million to transform London into cancer biotherapeutics hub
September 22, 2018 - Scientists predict how well the body will fight lung cancer by analyzing immune cell shapes
September 22, 2018 - New outbreak of rare eye disease identified in contact lens wearers
September 22, 2018 - Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections
September 22, 2018 - Research finds divide in dental health accessibility between city and regional areas
September 22, 2018 - Premature babies show better brain development when fed breast milk, finds study
September 22, 2018 - Novel system uses AI to detect abnormalities in fetal hearts
September 22, 2018 - UNC scientists reveal new approach to prevent obesity and diabetes
September 22, 2018 - CWRU receives NIH grant to learn how non-coding genes contribute to spread of colorectal cancer
September 22, 2018 - Scientists better understand influenza virus and how it spreads
September 22, 2018 - Scientists to focus on length of time when a person is alive and healthy
September 22, 2018 - Study shows positive financial impacts of Medicaid expansion for low-income Michigan residents
September 22, 2018 - Innovative approach for developing vaccine against most prevalent human malaria parasite
September 22, 2018 - Research scientist at Kessler Foundation receives $10,000 grant to study aphasia after stroke
September 22, 2018 - New findings on characteristics of Burning Mouth Syndrome
September 22, 2018 - Study sheds light on molecular mechanisms underlying progression of prion diseases
September 22, 2018 - Innovation Fund Denmark supports research project that aims to fight Clostridium difficile diarrhea
September 22, 2018 - Survey estimates caregiving costs for family members
September 22, 2018 - Inhibiting NF-kB improves heart function in a mouse model of Duchenne muscular dystrophy
September 22, 2018 - Introducing new EMR system may affect several aspects of clinic workflow
September 22, 2018 - Study finds why some human genes are more popular with biomedical researchers
September 22, 2018 - Finding epigenetic signature appears to predict inflammation risk in serious type of IBD
September 22, 2018 - Researchers develop light-based technique to measure very weak magnetic fields
September 22, 2018 - UAB researchers study dysfunction of the immune system associated with NSAID carprofen
September 22, 2018 - QIAGEN and DiaSorin launch automated, CE-marked workflow for high-throughput TB screening
September 22, 2018 - EFS checklist provides user-friendly tool for evaluating feeding skills in preterm infants
September 22, 2018 - Family history in blacks, Latinos associated with higher risk of AFib
September 22, 2018 - Researchers identify new genetic disorder in a human patient
September 22, 2018 - Cardiac MR With Contrast Feasible in Developing World
September 22, 2018 - Daily low-dose aspirin doesn’t reduce heart-attack risk in healthy people
September 21, 2018 - Children with asthma found to be disadvantaged in education and future occupation
September 21, 2018 - Interaction of chemical slurry and ancient shale in fracking wastewater causes radioactivity
September 21, 2018 - Scientists use mice to study transmission of Lyme disease bacteria by infected ticks
September 21, 2018 - Researchers find that sample size is key factor determining accuracy of study results
September 21, 2018 - Study shows how the drive to eat overpowers the brain’s signal to stop
September 21, 2018 - 30 Million Americans Now Have Diabetes
Tumor Cell Test Tops PSA for Survival in mCRPC

Tumor Cell Test Tops PSA for Survival in mCRPC

image_pdfDownload PDFimage_print

Action Points

  • Note that this analysis of data from 5 trials suggests that absence of circulating tumor cells performs better as a biomarker than change in PSA in terms of assessing response to therapy in metastatic, castration-resistant prostate cancer.
  • Be aware that the performance of this biomarker in clinical practice may be different than its performance in the context of a clinical trial.

Absence of circulating tumor cells (CTCs) after 13 weeks of treatment outperformed other potential markers of improved survival in patients with metastatic castration-resistant prostate cancer (mCRPC), a retrospective analysis of five randomized trials showed.

A decline in CTCs from nonzero at baseline to 0 at 13 weeks (CTC0) had a discriminatory power of 0.81 for predicting improved survival versus patients who did not achieve CTC0 status. The FDA-cleared response measure of CTC conversion (≥5 at baseline, ≤4 at 13 weeks) followed with a discriminatory power of 0.79. However, substantially more patients were evaluable for CTC0 than CTC conversion.

Six other response endpoints (CTC and PSA values) had discriminatory power ranging from 0.71 to 0.79, as reported online in the Journal of Clinical Oncology.

“The CTC0 endpoint is an indicator that cancer cells that were circulating in the blood are no longer detectable, an easily recognized outcome that is clinically meaningful to patients,” . “It is an outcome that occurs shortly after treatment initiation, providing researchers and practitioners with objective and reliable evidence that the therapy being administered had altered the patient’s prognosis in a favorable way.

“Taken together, the results of this study support the use of CTC0 as a response endpoint in early-phase clinical trials.”

The author of an accompanying editorial said that “the unambiguous interpretation of a positive and negative [CTC0] test should make this early efficacy marker an attractive intermediate endpoint for consideration of accelerated drug approval by regulatory bodies.”

“However, whether this endpoint should be used in routine clinical practice outside of a clinical trial (ie., as a measure of clinical benefit itself) is far less certain and seems premature at this time,” wrote Emanuel Antonarakis, MD, of Johns Hopkins University in Baltimore.

Antonarakis also acknowledged that PSA-based endpoints had less discriminatory power for predicting overall survival but pointed out that they could be evaluated in almost all patients across the five trials included in the analysis.

The need for clinically meaningful measures of response that occur early in the course of treatment for mCRPC has increased with the expansion of treatment options, including six new agents with diverse mechanisms of action approved since 2010. Each therapy’s approval was based on demonstration of a survival benefit in a large phase III trial, Scher and co-authors noted in their introduction.

In parallel with therapeutic expansion, advances in molecular profiling increased clinicians’ ability to identify subsets of patients and determine their likelihood of response to a given therapy. Historically, PSA-based tests were used to assess treatment efficacy, although the assessments did not provide a strong indication of survival, the authors continued.

In studies of mCRPC, patients with bone disease had higher numbers of CTCs compared with patients who have lymph node involvement, suggesting an association with metastatic spread. Inhibiting the spread of CTCs, therefore, should represent a clinically meaningful therapeutic objective, the authors continued. After phase II studies of abiraterone (Zytiga) and enzalutamide (Xtandi) showed CTC conversion rates of 30-40%, a research collaboration was formed in association with the FDA to study post-treatment CTC-based endpoints in phase III clinical trials.

Scher and colleagues reported findings from an analysis of short-term changes in CTC and PSA and their association with overall survival. The analysis comprised 6,081 patients with mCRPC from five prospective, randomized, phase III trials. Investigators examined the discriminatory power of CTC0 and CTC conversion at 13 weeks for identifying patients who would have improved survival. They also evaluated the endpoints of 30%, 50%, and 70% decreases in CTC count, as well as 30%, 50%, and 70% decreases in PSA level at 13 weeks.

To determine the discriminatory strength of each endpoint, investigators used assessment of the weighted c-index, which has a range of 0.5 to 1.0. A value of 0.5 reflected no discriminatory power between response and nonresponse, and a value of 1.0 indicated that almost all non-responding patients died before responding patients with the shortest survival. The analysis yielded the following discriminatory values:

  • CTC0: 0.81
  • CTC conversion: 0.79
  • CTC30: 0.72
  • CTC50: 0.72
  • CTC70: 0.73
  • PSA30: 0.71
  • PSA50: 0.72
  • PSA70: 0.74

The authors found that 75% of the patients could be evaluated for CTC0 compared with 51% for CTC conversion. As compared with a 70% decrease in PSA at 13 weeks, CTC0 offered significantly better discriminatory power (P=0.026) and, by extension, significantly better discrimination compared with PSA30 and PSA50.

“In addition to greater discrimination, the CTC0 and CTC conversion response endpoints were more robust, producing consistent weighted c-indices across the five trials,” the authors noted.

This work was partially supported by the FDA as part of a program to develop intermediate endpoints in castration-resistant prostate cancer. Some co-authors were employees of firms with commercial interests in such biomarkers.

Scher disclosed relationships with Asterias Biotherapeutics, Ferring Pharmaceuticals, WIRB-Copernicus Group, Merck, Clovis Oncology, Janssen Research & Development, Astellas Pharma, Sanofi, Physician’s Education Resource, OncLive Insights, Innocrin Pharmaceuticals, and Illumina.

Antonarakis disclosed relationships with Sanofi, Dendreon, Medivation, Janssen Biotech, ESSA, Astellas Pharma, Johnson & Johnson, Aragon Pharmaceuticals, Exelixis, Millennium, Genentech, Novartis, Tokai Pharmaceuticals, and patent/royalty/intellectual property interest.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2018-01-10T15:30:00-0500

Tagged with:

About author

Related Articles